Clinical Drug Investigation

, Volume 23, Issue 2, pp 69–84 | Cite as

Lansoprazole and Esomeprazole in Symptomatic GERD

A Double-Blind, Randomised, Multicentre Trial in 3000 Patients Confirms Comparable Symptom Relief
Original Research Article



To evaluate the onset and degree of symptom relief in a population of patients with symptomatic gastro-oesophageal reflux disease (GERD) treated with lansoprazole 30mg or esomeprazole 40mg, each administered once daily.


This was a phase IIIb, prospective, randomised, double-blind, active-controlled, multicentre study of patients with a history of symptomatic GERD.


Patients with symptomatic GERD based on preset criteria were randomised in a 1: 1 ratio to lansoprazole or esomeprazole for 2 weeks. Efficacy endpoints were the percentage of patients without daytime heartburn after the first treatment day, the percentage of patients without night-time heartburn after the first treatment day, and symptom relief (measured as percentage of days and nights without heartburn) and average symptom severity after the first day, during the first 3 days (primary efficacy endpoint), during the first week and during the 2-week treatment period.


3034 patients were randomised to lansoprazole 30mg (n = 1520) or esomeprazole 40mg (n = 1514). Patients in both treatment groups reported increases from baseline in the percentages of days and nights without heartburn and decreases in the average daytime and night-time heartburn severity during the 2-week treatment period. No statistically significant differences were observed between the lansoprazole 30mg and esomeprazole 40mg treatment groups in heartburn relief parameters on day 1 or during the first 3 days, the first week or the 2-week treatment period after adjusting for differences in baseline heartburn severity. Both treatments were well tolerated. Significantly higher percentages of patients treated with esomeprazole as compared with those treated with lansoprazole reported treatment-emergent dry mouth (0.5% vs 0.1 %, p = 0.021) and vomiting (0.5% vs 0.1%, p = 0.038). The most common treatment-related adverse events were diarrhoea (lansoprazole 1.4%, esomeprazole 1.8%), flatulence (lansoprazole 0.7%, esomeprazole 1.0%) and abdominal pain (lansoprazole 1.1%, esomeprazole 1.3%).


Lansoprazole 30mg once daily or esomeprazole 40mg once daily for 2 weeks effectively increase the percentage of days and nights patients with symptomatic GERD are without heartburn and reduce the average severity of daytime and night-time heartburn.



This research was supported by a grant from TAP Pharmaceutical Products Inc., Lake Forest, Illinois, USA.

We wish to thank the participating investigators (see Appendix) for their contribution to the study, and TAP Pharmaceutical Products Inc., Lake Forest, Illinois, USA for their support.


  1. 1.
    Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole Study Group. Am J Gastroenterol 2000; 95: 1894–9PubMedCrossRefGoogle Scholar
  2. 2.
    Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treatment with newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998–1017PubMedCrossRefGoogle Scholar
  3. 3.
    Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625–32PubMedCrossRefGoogle Scholar
  4. 4.
    Richter JE, Sabesin SM, Kogut DG, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996; 91: 1766–72PubMedGoogle Scholar
  5. 5.
    Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ’standard doses’ of H2-receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145–55PubMedCrossRefGoogle Scholar
  6. 6.
    Robinson M, Sahba B, Avner D, et al. Comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25–31PubMedCrossRefGoogle Scholar
  7. 7.
    Jones RH, Baxter G, Lansoprazole 30mg daily versus ranitidine 150mg bd in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1998; 11: 541–546CrossRefGoogle Scholar
  8. 8.
    Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529–39PubMedCrossRefGoogle Scholar
  9. 9.
    Winters C, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118–24PubMedGoogle Scholar
  10. 10.
    Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97(8): 1901–9PubMedGoogle Scholar
  11. 11.
    Huang JQ, Sridhar S, Hunt RH. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors: a meta-analysis of comparative trials. [Abstract.] Gut 1999; 45: P513CrossRefGoogle Scholar
  12. 12.
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65PubMedCrossRefGoogle Scholar
  13. 13.
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83PubMedCrossRefGoogle Scholar
  14. 14.
    Howden CW, Ballard D, Robieson W. Evidence of therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22(2): 99–109CrossRefGoogle Scholar
  15. 15.
    Dohmen W, Fuchs W, Seelis REA. Onset and duration of pain relief in gastro-esophageal reflux disease (GERD): a clinical comparison of lansoprazole, omeprazole MUPS and esomeprazole [abstract]. Gastroenterology 2002; 122 Suppl. 1: A201Google Scholar
  16. 16.
    Vakil NB, Zuckerman S, Levine JG. Nocturnal heartburn in patients with erosive esophagitis and its resolution with proton pump inhibitors [abstract]. Gastroenterology 2002; 122 Suppl. 1: A200Google Scholar
  17. 17.
    Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321–9PubMedCrossRefGoogle Scholar
  18. 18.
    van Eiteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Statis Inst 1960; 37: 351–61Google Scholar
  19. 19.
    Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45–52PubMedCrossRefGoogle Scholar
  20. 20.
    The Gallup Organization. A Gallup Organization National Survey: Understanding heartburn in America. Princeton, NJ: The Gallup Organization. May 2000Google Scholar
  21. 21.
    Richter JE, Kahrilas PJ, Sontag SJ, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089–98PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.University of Michigan Health SystemAnn ArborUSA
  2. 2.Abbott LaboratoriesAbbott ParkUSA
  3. 3.TAP Pharmaceutical Products Inc.Lake ForestUSA

Personalised recommendations